Name: Funding for health tech - Matthew Stork, Cambridge Cognition
Uploaded: 2022-05-08T21:57:34.965154+00:00
Duration: 1074 s
Channel: UK Investor Show
Description: Zak Mir and Matthew Stork discuss how difficult it can be for novel health tech companies to land funding

Zak Mir and Matthew Stork  discuss how difficult it can be for novel health tech companies to land funding

<p>Zak Mir and Matthew Stork  discuss how difficult it can be for novel health tech companies to land funding</p>

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/003/697/003697/video_m7PD7FL.mp4#t=144

UK Investor Show

Funding for health tech - Matthew Stork, Cambridge Cognition

Covid helped us accelerate - Tony Dyer, Belluscura

How to make money from heath tech - Matthew Stork, Cambridge Cognition

Selling Belluscura's products - Tony Dyer, Belluscura

The effect of an ageing population - Tony Dyer, Belluscura and Matthew Stork, Cambridge Cognition

Diversifying the business - Tony Dyer, Belluscura and Matthew Stork, Cambridge Cognition

UK Investor Summit - Main Stage - Saturday 2nd October 2021

<p>UK Investor Summit - Main Stage - Saturday 2nd October 2021</p>

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/003/697/003697/video_m7PD7FL.mp4

Zak Mir and Tony Dyer discuss Belluscura's recent journey and the boost it has received from Covid as the need for its oxygen concentrators became much better understood and needed, culminating in an AIM IPO raising £17.5 million

Zak Mir and Matthew Stork discuss moving from raising funds to initial sales to profitability within health tech and the different phases and customers that you need for success

Zak Mir and Tony Dyer discuss how Belluscura approaches the market and sells its products having recently launched its first products into the market

Zak Mir, Tony Dyer and Matthew Stork discuss how the ageing population is impacting the heath tech sector and their respective businesses.

Zak Mir, Tony Dyer and Matthew Stork discuss whether they have plans to diversify their businesses away from their primary product lines.